Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
Completed · Phase 1/Phase 2
Conditions studied: Multiple Myeloma
In brief
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
Key facts
- Study ID
- NCT00186316
- Run by
- Stanford University
- People needed
- 30
- Starts
- 2003-04-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2009-08-25
Who can join
Age: 17 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.